77 results on '"Gilgenkrantz, H."'
Search Results
2. Distal Transcript of the Dystrophin Gene Initiated from an Alternative First Exon and Encoding a 75-kDa Protein Widely Distributed in Nonmuscle Tissues
- Author
-
Hugnot, J. P., Gilgenkrantz, H., Vincent, N., Chafey, P., Morris, G. E., Monaco, A. P., Berwald-Netter, Y., Koulakoff, A., Kaplan, J. C., Kahn, A., and Chelly, J.
- Published
- 1992
3. In vivo assessment of fibrosis in murine liver using transient microelastography: a feasibility study.
- Author
-
Bastard, C., Bosisio, M., Yorgov, M., Gilgenkrantz, H., and Sandrin, L.
- Published
- 2009
- Full Text
- View/download PDF
4. Transcriptional profiling of liver regeneration: new approaches to an old trick!
- Author
-
Mitchell, C. and Gilgenkrantz, H.
- Published
- 2003
- Full Text
- View/download PDF
5. 12 REGRESSION OF HEPATITIS C-RELATED CIRRHOSIS AND LONG-TERM SURVIVAL
- Author
-
Mallet, V., Gilgenkrantz, H., Serpaggi, J., Verkarre, V., Vallet-Pichard, A., Fontaine, H., and Pol, S.
- Published
- 2008
- Full Text
- View/download PDF
6. O59 MICE WITH AXIN-1 LIVER SPECIFIC DELETION DEVELOP HEPATOCELLULAR CARCINOMAS WITHOUT BETA-CATENIN ACTIVATION.
- Author
-
Dahmani, R., Tournier, E., Coulouarn, C., Just, P.-A., Terris, B., Gilgenkrantz, H., and Perret, C.
- Subjects
- *
AXIN , *LABORATORY mice , *LIVER cancer , *CATENINS , *MEDICAL research - Published
- 2014
- Full Text
- View/download PDF
7. 937 GROWTH HORMONE RECEPTOR PLAYS A CRITICAL ROLE IN LIVER REGENERATION VIA THE EPIDERMAL GROWTH FACTOR RECEPTOR PATHWAY
- Author
-
Zerrad-Saadi, A., Lambert-Blot, M., Bretes-Rodrigues, H., Mitchell, C., Sotiropoulos, A., Kopchick, J.J., Gilgenkrantz, H., and Guidotti, J.-E.
- Published
- 2010
- Full Text
- View/download PDF
8. Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy.
- Author
-
Gilgenkrantz H, Sayegh RA, and Lotersztajn S
- Abstract
Liver fibrosis develops in response to chronic liver injury and is characterized by a sustained inflammatory response that leads to excessive collagen deposition by myofibroblasts. The fibrogenic response is governed by the release of inflammatory mediators from innate, adaptive, and innate-like lymphoid cells and from nonprofessional immune cells (i.e., epithelial cells, hepatic myofibroblasts, and liver sinusoidal endothelial cells). Upon removal of the underlying cause, liver fibrosis can resolve via activation of specific immune cell subsets. Despite major advances in the understanding of fibrosis pathogenesis, there is still no approved antifibrotic therapy. This review summarizes our current knowledge of the immune cell landscape and the inflammatory mechanisms underlying liver fibrosis progression and regression. We discuss how reprogramming immune cell phenotype, in particular through targeting selective inflammatory pathways or modulating cell-intrinsic metabolism, may be translated into antifibrogenic therapies.
- Published
- 2024
- Full Text
- View/download PDF
9. Endothelial autophagy is not required for liver regeneration after partial hepatectomy in mice with fatty liver.
- Author
-
Hammoutene A, Tanguy M, Calmels M, Pravisani R, Albuquerque M, Casteleyn C, Slimani L, Sadoine J, Boulanger CM, Paradis V, Gilgenkrantz H, and Rautou PE
- Subjects
- Mice, Animals, Hepatectomy methods, Liver Regeneration, Endothelial Cells metabolism, Liver metabolism, Diet, High-Fat, Choline metabolism, Methionine metabolism, Autophagy, Mice, Inbred C57BL, Disease Models, Animal, Non-alcoholic Fatty Liver Disease metabolism, Focal Nodular Hyperplasia
- Abstract
Background & Aims: Patients with non-alcoholic fatty liver disease (NAFLD) have impaired liver regeneration. Liver endothelial cells play a key role in liver regeneration. In non-alcoholic steatohepatitis (NASH), liver endothelial cells display a defect in autophagy, contributing to NASH progression. We aimed to determine the role of endothelial autophagy in liver regeneration following liver resection in NAFLD., Methods: First, we assessed autophagy in primary endothelial cells from wild type mice fed a high fat diet and subjected to partial hepatectomy. Then, we assessed liver regeneration after partial hepatectomy in mice deficient (Atg5
lox/lox ;VE-cadherin-Cre+ ) or not (Atg5lox/lox ) in endothelial autophagy and fed a high fat diet. The role of endothelial autophagy in liver regeneration was also assessed in ApoE-/- hypercholesterolemic mice and in mice with NASH induced by methionine- and choline-deficient diet., Results: First, autophagy (LC3II/protein) was strongly increased in liver endothelial cells following hepatectomy. Then, we observed at 40 and 48 h and at 7 days after partial hepatectomy, that Atg5lox/lox ;VE-cadherin-Cre+ mice fed a high fat diet had similar liver weight, plasma AST, ALT and albumin concentration, and liver protein expression of proliferation (PCNA), cell-cycle (Cyclin D1, BrdU incorporation, phospho-Histone H3) and apoptosis markers (cleaved Caspase-3) as Atg5lox/lox mice fed a high fat diet. Same results were obtained in ApoE-/- and methionine- and choline-deficient diet fed mice, 40 h after hepatectomy., Conclusion: These results demonstrate that the defect in endothelial autophagy occurring in NASH does not account for the impaired liver regeneration occurring in this setting., (© 2023 The Authors. Liver International published by John Wiley & Sons Ltd.)- Published
- 2023
- Full Text
- View/download PDF
10. Cell metabolism-based therapy for liver fibrosis, repair, and hepatocellular carcinoma.
- Author
-
Gilgenkrantz H, Paradis V, and Lotersztajn S
- Abstract
Progression of chronic liver injury to fibrosis, abnormal liver regeneration, and HCC is driven by a dysregulated dialog between epithelial cells and their microenvironment, in particular immune, fibroblasts, and endothelial cells. There is currently no antifibrogenic therapy, and drug treatment of HCC is limited to tyrosine kinase inhibitors and immunotherapy targeting the tumor microenvironment. Metabolic reprogramming of epithelial and nonparenchymal cells is critical at each stage of disease progression, suggesting that targeting specific metabolic pathways could constitute an interesting therapeutic approach. In this review, we discuss how modulating intrinsic metabolism of key effector liver cells might disrupt the pathogenic sequence from chronic liver injury to fibrosis/cirrhosis, regeneration, and HCC., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
11. Monoacylglycerol lipase reprograms hepatocytes and macrophages to promote liver regeneration.
- Author
-
Allaire M, Al Sayegh R, Mabire M, Hammoutene A, Siebert M, Caër C, Cadoux M, Wan J, Habib A, Le Gall M, de la Grange P, Guillou H, Postic C, Paradis V, Lotersztajn S, and Gilgenkrantz H
- Abstract
Background & Aims: Liver regeneration is a repair process in which metabolic reprogramming of parenchymal and inflammatory cells plays a major role. Monoacylglycerol lipase (MAGL) is an ubiquitous enzyme at the crossroad between lipid metabolism and inflammation. It converts monoacylglycerols into free fatty acids and metabolises 2-arachidonoylglycerol into arachidonic acid, being thus the major source of pro-inflammatory prostaglandins in the liver. In this study, we investigated the role of MAGL in liver regeneration., Methods: Hepatocyte proliferation was studied in vitro in hepatoma cell lines and ex vivo in precision-cut human liver slices. Liver regeneration was investigated in mice treated with a pharmacological MAGL inhibitor, MJN110, as well as in animals globally invalidated for MAGL (MAGL
-/- ) and specifically invalidated in hepatocytes (MAGLHep-/- ) or myeloid cells (MAGLMye-/- ). Two models of liver regeneration were used: acute toxic carbon tetrachloride injection and two-thirds partial hepatectomy. MAGLMye-/- liver macrophages profiling was analysed by RNA sequencing. A rescue experiment was performed by in vivo administration of interferon receptor antibody in MAGLMye-/- mice., Results: Precision-cut human liver slices from patients with chronic liver disease and human hepatocyte cell lines exposed to MJN110 showed reduced hepatocyte proliferation. Mice with global invalidation or mice treated with MJN110 showed blunted liver regeneration. Moreover, mice with specific deletion of MAGL in either hepatocytes or myeloid cells displayed delayed liver regeneration. Mechanistically, MAGLHep-/- mice showed reduced liver eicosanoid production, in particular prostaglandin E2 that negatively impacts on hepatocyte proliferation. MAGL inhibition in macrophages resulted in the induction of the type I interferon pathway. Importantly, neutralising the type I interferon pathway restored liver regeneration of MAGLMye-/- mice., Conclusions: Our data demonstrate that MAGL promotes liver regeneration by hepatocyte and macrophage reprogramming., Impact and Implications: By using human liver samples and mouse models of global or specific cell type invalidation, we show that the monoacylglycerol pathway plays an essential role in liver regeneration. We unveil the mechanisms by which MAGL expressed in both hepatocytes and macrophages impacts the liver regeneration process, via eicosanoid production by hepatocytes and the modulation of the macrophage interferon pathway profile that restrains hepatocyte proliferation., (© 2023 The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
12. MAIT cell inhibition promotes liver fibrosis regression via macrophage phenotype reprogramming.
- Author
-
Mabire M, Hegde P, Hammoutene A, Wan J, Caër C, Sayegh RA, Cadoux M, Allaire M, Weiss E, Thibault-Sogorb T, Lantz O, Goodhardt M, Paradis V, de la Grange P, Gilgenkrantz H, and Lotersztajn S
- Subjects
- Humans, Male, Mice, Animals, Liver Cirrhosis pathology, Macrophages, Liver pathology, Fibrosis, Phenotype, Mice, Inbred C57BL, Mucosal-Associated Invariant T Cells, Non-alcoholic Fatty Liver Disease pathology
- Abstract
Recent data have shown that liver fibrosis can regress even at later stages of cirrhosis and shifting the immune response from pro-inflammatory towards a resolutive profile is considered as a promising option. The immune regulatory networks that govern the shift of the inflammatory phenotype and thus potential reversal of liver fibrosis are lesser known. Here we show that in precision-cut human liver slices obtained from patients with end-stage fibrosis and in mouse models, inhibiting Mucosal-Associated Invariant T (MAIT) cells using pharmacological or antibody-driven approaches, limits fibrosis progression and even regresses fibrosis, following chronic toxic- or non-alcoholic steatohepatitis (NASH)-induced liver injury. Mechanistic studies, combining RNA sequencing, in vivo functional studies (performed in male mice) and co-culture experiments indicate that disruption of the MAIT cell-monocyte/macrophage interaction results in resolution of fibrosis both by increasing the frequency of restorative Ly6C
lo at the expenses of pro-fibrogenic Ly6Chi monocyte-derived macrophages and promoting an autophagic phenotype in both subsets. Thus, our data show that MAIT cell activation and the consequential phenotype shift of liver macrophages are important pathogenic features of liver fibrosis and could be targeted by anti-fibrogenic therapy., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
13. Targeting cell-intrinsic metabolism for antifibrotic therapy.
- Author
-
Gilgenkrantz H, Mallat A, Moreau R, and Lotersztajn S
- Subjects
- Animals, Antifibrotic Agents pharmacology, Cholesterol metabolism, Glycolysis drug effects, Humans, Lipogenesis drug effects, Liver Cirrhosis complications, Liver Cirrhosis immunology, Lymphocytes immunology, Macrophages immunology, Non-alcoholic Fatty Liver Disease complications, Non-alcoholic Fatty Liver Disease immunology, Antifibrotic Agents therapeutic use, Hepatic Stellate Cells metabolism, Hepatocytes metabolism, Liver Cirrhosis drug therapy, Liver Cirrhosis metabolism, Lymphocytes metabolism, Macrophages metabolism, Non-alcoholic Fatty Liver Disease drug therapy, Non-alcoholic Fatty Liver Disease metabolism, Signal Transduction drug effects
- Abstract
In recent years, there have been major advances in our understanding of the mechanisms underlying fibrosis progression and regression, and how coordinated interactions between parenchymal and non-parenchymal cells impact on the fibrogenic process. Recent studies have highlighted that metabolic reprogramming of parenchymal cells, immune cells (immunometabolism) and hepatic stellate cells is required to support the energetic and anabolic demands of phenotypic changes and effector functions. In this review, we summarise how targeting cell-intrinsic metabolic modifications of the main fibrogenic cell actors may impact on fibrosis progression and we discuss the antifibrogenic potential of metabolically targeted interventions., Competing Interests: Conflict of interest The authors declare no competing financial interests. Please refer to the accompanying ICMJE disclosure forms for further details., (Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
14. LC3-associated phagocytosis in myeloid cells, a fireman that restrains inflammation and liver fibrosis, via immunoreceptor inhibitory signaling.
- Author
-
Wan J, Weiss E, Ben Mkaddem S, Mabire M, Choinier PM, Thibault-Sogorb T, Hegde P, Bens M, Broer L, Gilgenkrantz H, Moreau R, Saveanu L, Codogno P, Monteiro RC, and Lotersztajn S
- Subjects
- Humans, Inflammation blood, Liver Cirrhosis blood, Inflammation pathology, Liver Cirrhosis pathology, Microtubule-Associated Proteins metabolism, Myeloid Cells metabolism, Myeloid Cells pathology, Phagocytosis, Signal Transduction
- Abstract
Control of systemic and hepatic inflammation, in particular originating from monocytes/macrophages, is crucial to prevent liver fibrosis and its progression to end-stage cirrhosis. LC3-associated phagocytosis (LAP) is a non-canonical form of autophagy that shifts the monocyte/macrophage phenotype to an anti-inflammatory phenotype. In a recent study, we uncovered LAP as a protective mechanism against inflammation-driven liver fibrosis and systemic inflammation in the context of cirrhosis. We observed that LAP is enhanced in blood and liver monocytes from patients with liver fibrosis or those who progress to cirrhosis. Combining studies in which LAP was pharmacologically or genetically inactivated, we found that LAP limits inflammation in monocytes from cirrhotic patients, and the hepatic inflammatory profile in mice with chronic liver injury, resulting in anti-fibrogenic effects. Mechanistically, LAP-induced anti-inflammatory and antifibrogenic signaling results from enhanced expression of the Fc immunoreceptor FCGR2A/FcγRIIA and activation of an FCGR2A-mediated PTPN6/SHP-1 anti-inflammatory pathway, leading to increased engulfment of IgG into LC3
+ phagosomes. In patients with cirrhosis progressing to multi-organ failure (acute-on chronic liver failure), LAP is lost in monocytes, and can be restored by targeting FCGR2A-mediated PTPN6/SHP-1 signaling. These data suggest that sustaining LAP may open novel therapeutic perspectives for patients with end-stage liver disease.- Published
- 2020
- Full Text
- View/download PDF
15. LC3-associated phagocytosis protects against inflammation and liver fibrosis via immunoreceptor inhibitory signaling.
- Author
-
Wan J, Weiss E, Ben Mkaddem S, Mabire M, Choinier PM, Picq O, Thibault-Sogorb T, Hegde P, Pishvaie D, Bens M, Broer L, Gilgenkrantz H, Moreau R, Saveanu L, Codogno P, Monteiro RC, and Lotersztajn S
- Subjects
- Animals, Humans, Inflammation, Mice, Mice, Inbred C57BL, Microtubule-Associated Proteins, Liver Cirrhosis, Phagocytosis, Signal Transduction
- Abstract
Sustained hepatic and systemic inflammation, particularly originating from monocytes/macrophages, is a driving force for fibrosis progression to end-stage cirrhosis and underlies the development of multiorgan failure. Reprogramming monocyte/macrophage phenotype has emerged as a strategy to limit inflammation during chronic liver injury. Here, we report that LC3-associated phagocytosis (LAP), a noncanonical form of autophagy, protects against hepatic and systemic inflammation during chronic liver injury in rodents, with beneficial antifibrogenic effects. LAP is enhanced in blood and liver monocytes from patients with fibrosis and cirrhosis. Pharmacological inhibition of LAP components in human monocytes from patients with cirrhosis or genetic disruption of LAP in mice with chronic liver injury exacerbates both the inflammatory signature in isolated human monocytes and the hepatic inflammatory profile in mice, resulting in enhanced liver fibrosis. Mechanistically, patients with cirrhosis showed increased monocyte expression of Fc fragment of IgG receptor IIA (FcγRIIA) and enhanced engulfment of immunoglobulin G in LC3
+ phagosomes that triggers an FcγRIIA/Src homology region 2 domain-containing phosphatase-1 (SHP-1) inhibitory immunoreceptor tyrosine-based activation motif (ITAMi) anti-inflammatory pathway. Mice overexpressing human FcγRIIA in myeloid cells show enhanced LAP in response to chronic liver injury and resistance to inflammation and liver fibrosis. Activation of LAP is lost in monocytes from patients with multiorgan failure and restored by specifically targeting ITAMi signaling with anti-FcγRIIA F(ab')2 fragments, or with intravenous immunoglobulin (IVIg). These data suggest the existence of an ITAMi-mediated mechanism by which LAP might protect against inflammation. Sustaining LAP may open therapeutic perspectives for patients with chronic liver disease., (Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.)- Published
- 2020
- Full Text
- View/download PDF
16. The aged liver: Beyond cellular senescence.
- Author
-
Allaire M and Gilgenkrantz H
- Subjects
- Aged, Homeostasis, Humans, Liver physiology, Liver Diseases etiology, Aging pathology, Cellular Senescence, Liver pathology
- Abstract
The aging of the population, the increased prevalence of chronic liver diseases in elderly and the need to broaden the list of potential liver donors enjoin us to better understand what is an aged liver. In this review, we provide a brief introduction to cellular senescence, revisit the main morphological and functional modifications of the liver induced by aging, particularly concerning metabolism, immune response and regeneration, and try to elude some of the signalling pathways responsible for these modifications. Finally, we discuss the clinical consequences of aging on chronic liver diseases and the implications of older age for donors and recipients in liver transplantation., (Copyright © 2019. Published by Elsevier Masson SAS.)
- Published
- 2020
- Full Text
- View/download PDF
17. Letter to the Editor: Comment on Qiao et al.
- Author
-
Gilgenkrantz H and Perret C
- Subjects
- Animals, Diagnostic Tests, Routine, Mice, Sequence Deletion, Carcinogenesis, beta Catenin
- Published
- 2019
- Full Text
- View/download PDF
18. Age and liver transplantation.
- Author
-
Durand F, Levitsky J, Cauchy F, Gilgenkrantz H, Soubrane O, and Francoz C
- Subjects
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Brain Death, Cadaver, Donor Selection, Female, Graft Survival, Humans, Liver Transplantation mortality, Male, Middle Aged, Risk Factors, Transplants, Waiting Lists mortality, Young Adult, Aging, Liver Transplantation methods, Living Donors, Transplant Recipients
- Abstract
The average age of liver transplant donors and recipients has increased over the years. Independent of the cause of liver disease, older candidates have more comorbidities, higher waitlist mortality and higher post-transplant mortality than younger patients. However, transplant benefit may be similar in older and younger recipients, provided older recipients are carefully selected. The cohort of elderly patients transplanted decades ago is also increasingly raising issues concerning long-term exposure to immunosuppression and aging of the transplanted liver. Excellent results can be achieved with elderly donors and there is virtually no upper age limit for donors after brain death liver transplantation. The issue is how to optimise selection, procurement and matching to ensure good results with elderly donors. The impact of old donor age is more pronounced in younger recipients and patients with a high model for end-stage liver disease score. Age matching between the donor and the recipient should be incorporated into allocation policies with a multistep approach. However, age matching may vary depending on the objectives of different allocation policies. In addition, age matching must be revisited in the era of direct-acting antivirals. More restrictive limits have been adopted in donation after circulatory death. Perfusion machines which are currently under investigation may help expand these limits. In living donor liver transplantation, donor age limit is essentially guided by morbidity related to procurement. In this review we summarise changing trends in recipient and donor age. We discuss the implications of older age donors and recipients. We also consider different options for age matching in liver transplantation that could improve outcomes., (Copyright © 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
19. β-catenin-activated hepatocellular carcinomas are addicted to fatty acids.
- Author
-
Senni N, Savall M, Cabrerizo Granados D, Alves-Guerra MC, Sartor C, Lagoutte I, Gougelet A, Terris B, Gilgenkrantz H, Perret C, Colnot S, and Bossard P
- Subjects
- Animals, Epoxy Compounds pharmacology, Gene Expression Regulation, Neoplastic, Humans, Mice, Knockout, Mutation, Oxidation-Reduction, PPAR alpha physiology, beta Catenin genetics, Carcinoma, Hepatocellular genetics, Carcinoma, Hepatocellular metabolism, Fatty Acids metabolism, Liver Neoplasms genetics, Liver Neoplasms metabolism, beta Catenin metabolism
- Abstract
Objectives: CTNNB1 -mutated hepatocellular carcinomas (HCCs) constitute a major part of human HCC and are largely inaccessible to target therapy. Yet, little is known about the metabolic reprogramming induced by β-catenin oncogenic activation in the liver. We aimed to decipher such reprogramming and assess whether it may represent a new avenue for targeted therapy of CTNNB1 -mutated HCC., Design: We used mice with hepatocyte-specific oncogenic activation of β-catenin to evaluate metabolic reprogramming using metabolic fluxes on tumourous explants and primary hepatocytes. We assess the role of Pparα in knock-out mice and analysed the consequences of fatty acid oxidation (FAO) using etomoxir. We explored the expression of the FAO pathway in an annotated human HCC dataset., Results: β-catenin-activated HCC were not glycolytic but intensively oxidised fatty acids. We found that Pparα is a β-catenin target involved in FAO metabolic reprograming. Deletion of Pparα was sufficient to block the initiation and progression of β-catenin-dependent HCC development. FAO was also enriched in human CTNNB1 -mutated HCC, under the control of the transcription factor PPARα., Conclusions: FAO induced by β-catenin oncogenic activation in the liver is the driving force of the β-catenin-induced HCC. Inhibiting FAO by genetic and pharmacological approaches blocks HCC development, showing that inhibition of FAO is a suitable therapeutic approach for CTNNB1 -mutated HCC., Competing Interests: Competing interests: None declared., (© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.)
- Published
- 2019
- Full Text
- View/download PDF
20. The impact of steatosis on liver regeneration.
- Author
-
Allaire M and Gilgenkrantz H
- Subjects
- Animals, Humans, Liver drug effects, Liver metabolism, Signal Transduction, Fatty Liver physiopathology, Liver pathology, Liver Regeneration
- Abstract
Alcoholic and non-alcoholic fatty liver diseases are the leading causes of cirrhosis in Western countries. These chronic liver diseases share common pathological features ranging from steatosis to steatohepatitis. Fatty liver is associated with primary liver graft dysfunction, a higher incidence of complications/mortality after surgery, in correlation with impaired liver regeneration. Liver regeneration is a multistep process including a priming phase under the control of cytokines followed by a growth factor receptor activation phase leading to hepatocyte proliferation. This process ends when the initial liver mass is restored. Deficiency in epidermal growth factor receptor (EGFR) liver expression, reduced expression of Wee1 and Myt1 kinases, oxidative stress and alteration in hepatocyte macroautophagy have been identified as mechanisms involved in the defective regeneration of fatty livers. Besides the mechanisms, we will also discuss in this review various treatments that have been investigated in the reversal of the regeneration defect, for example, omega-3 fatty acids, pioglitazone, fibroblast growth factor (FGF)19-based chimeric molecule or growth hormone (GH). Since dysbiosis impedes liver regeneration, targeting microbiota could also be an interesting therapeutic approach.
- Published
- 2018
- Full Text
- View/download PDF
21. Understanding Liver Regeneration: From Mechanisms to Regenerative Medicine.
- Author
-
Gilgenkrantz H and Collin de l'Hortet A
- Subjects
- Animals, Humans, Hepatocytes cytology, Liver Diseases therapy, Liver Regeneration, Regenerative Medicine
- Abstract
Liver regeneration is a complex and unique process. When two-thirds of a mouse liver is removed, the remaining liver recovers its initial weight in approximately 10 days. The understanding of the mechanisms responsible for liver regeneration may help patients needing large liver resections or transplantation and may be applied to the field of regenerative medicine. All differentiated hepatocytes are capable of self-renewal, but different subpopulations of hepatocytes seem to have distinct proliferative abilities. In the setting of chronic liver diseases, a ductular reaction ensues in which liver progenitor cells (LPCs) proliferate in the periportal region. Although these LPCs have the capacity to differentiate into hepatocytes and biliary cells in vitro, their ability to participate in liver regeneration is far from clear. Their expansion has even been associated with increased fibrosis and poorer prognosis in chronic liver diseases. Controversies also remain on their origin: lineage studies in experimental mouse models of chronic injury have recently suggested that these LPCs originate from hepatocyte dedifferentiation, whereas in other situations, they seem to come from cholangiocytes. This review summarizes data published in the past 5 years in the liver regeneration field, discusses the mechanisms leading to regeneration disruption in chronic liver disorders, and addresses the potential use of novel approaches for regenerative medicine., (Copyright © 2018 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
22. Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver.
- Author
-
Hegde P, Weiss E, Paradis V, Wan J, Mabire M, Sukriti S, Rautou PE, Albuquerque M, Picq O, Gupta AC, Ferrere G, Gilgenkrantz H, Kiaf B, Toubal A, Beaudoin L, Lettéron P, Moreau R, Lehuen A, and Lotersztajn S
- Subjects
- Adult, Aged, Animals, Cell Count, Cells, Cultured, Coculture Techniques, Female, Humans, Liver immunology, Liver pathology, Liver Cirrhosis blood, Liver Cirrhosis pathology, Male, Mice, Middle Aged, Non-alcoholic Fatty Liver Disease blood, Non-alcoholic Fatty Liver Disease pathology, Liver Cirrhosis immunology, Macrophages immunology, Mucosal-Associated Invariant T Cells immunology, Non-alcoholic Fatty Liver Disease immunology
- Abstract
Liver fibrosis is the common response to chronic liver injury, and leads to cirrhosis and its complications. Persistent inflammation is a driving force of liver fibrosis progression. Mucosal-associated invariant T (MAIT) cells are non-conventional T cells that display altered functions during chronic inflammatory diseases. Here, we show that circulating MAIT cells are reduced in patients with alcoholic or non-alcoholic fatty liver disease-related cirrhosis while they accumulate in liver fibrotic septa. Using two models of chronic liver injury, we demonstrate that MAIT cell-enriched mice show increased liver fibrosis and accumulation of hepatic fibrogenic cells, whereas MAIT cell-deficient mice are resistant. Co-culture experiments indicate that MAIT cells enhance the proinflammatory properties of monocyte-derived macrophages, and promote mitogenic and proinflammatory functions of fibrogenic cells, via distinct mechanisms. Our results highlight the profibrogenic functions of MAIT cells and suggest that targeting MAIT cells may constitute an attractive antifibrogenic strategy during chronic liver injury.
- Published
- 2018
- Full Text
- View/download PDF
23. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
- Author
-
Abitbol S, Dahmani R, Coulouarn C, Ragazzon B, Mlecnik B, Senni N, Savall M, Bossard P, Sohier P, Drouet V, Tournier E, Dumont F, Sanson R, Calderaro J, Zucman-Rossi J, Vasseur-Cognet M, Just PA, Terris B, Perret C, and Gilgenkrantz H
- Subjects
- Animals, Axin Protein genetics, Carcinogenesis genetics, Carcinogenesis metabolism, Carcinoma, Hepatocellular genetics, Hepatocytes metabolism, Humans, Liver Neoplasms genetics, Liver Neoplasms, Experimental etiology, Liver Neoplasms, Experimental genetics, Liver Neoplasms, Experimental metabolism, Male, Mice, Mice, Knockout, Mutation, Prognosis, Receptors, Notch genetics, Receptors, Notch metabolism, Wnt Signaling Pathway genetics, beta Catenin metabolism, Axin Protein deficiency, Carcinoma, Hepatocellular etiology, Carcinoma, Hepatocellular metabolism, Liver Neoplasms etiology, Liver Neoplasms metabolism
- Abstract
Background & Aims: The Wnt/β-catenin pathway is the most frequently deregulated pathway in hepatocellular carcinoma (HCC). Inactivating mutations of the gene encoding AXIN1, a known negative regulator of the Wnt/β-catenin signaling pathway, are observed in about 10% of HCCs. Whole-genome studies usually place HCC with AXIN1 mutations and CTNNB1 mutations in the group of tumors with Wnt/β-catenin activated program. However, it has been shown that HCCs with activating CTNNB1 mutations form a group of HCCs, with a different histology, prognosis and genomic signature to those with inactivating biallelic AXIN1 mutations. We aimed to elucidate the relationship between CTNNB1 mutations, AXIN1 mutations and the activation level of the Wnt/β-catenin program., Methods: We evaluated two independent human HCC datasets for the expression of a 23-β-catenin target genes program. We modeled Axin1 loss of function tumorigenesis in two engineered mouse models and performed gene expression profiling., Results: Based on gene expression, we defined three levels of β-catenin program activation: strong, weak or no activation. While more than 80% CTNNB1-mutated tumors were found in the strong or in the weak activation program, most of the AXIN1-mutated tumors (>70%) were found in the subgroup with no activation. We validated this result by demonstrating that mice with a hepatocyte specific AXIN1 deletion developed HCC in the absence of β-catenin induction. We defined a 329-gene signature common in human and mouse AXIN1 mutated HCC that is highly enriched in Notch and YAP oncogenic signatures., Conclusions: AXIN1-mutated HCCs occur independently of the Wnt/β-catenin pathway and involve Notch and YAP pathways. These pathways constitute potentially interesting targets for the treatment of HCC caused by AXIN1 mutations., Lay Summary: Liver cancer has a poor prognosis. Defining the molecular pathways involved is important for developing new therapeutic approaches. The Wnt/β-catenin pathway is the most frequently deregulated pathway in hepatocellular carcinoma (HCC). Mutations of AXIN1, a member of this pathway, represent about 10% of HCC mutations. Using both human HCC collections and engineered mouse models of liver cancers with AXIN1 mutation or deletion, we defined a common signature of liver tumors mutated for AXIN1 and demonstrate that these tumors occur independently of the activation of the Wnt/β-catenin pathway., (Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
24. Pre-therapy liver transcriptome landscape in Indian and French patients with severe alcoholic hepatitis and steroid responsiveness.
- Author
-
Sharma S, Maras JS, Das S, Hussain S, Mishra AK, Shasthry SM, Sharma CB, Weiss E, Elkrief L, Rautou PE, Gilgenkrantz H, Lotersztajn S, Paradis V, de la Grange P, Junot C, Moreau R, and Sarin SK
- Subjects
- Adult, Cell Proliferation, Ethnicity, Fatty Liver, Alcoholic drug therapy, Fatty Liver, Alcoholic ethnology, Fatty Liver, Alcoholic genetics, Female, Glucocorticoids therapeutic use, Hepatocytes metabolism, Hepatocytes physiology, Humans, Male, Middle Aged, Receptors, Glucocorticoid genetics, Receptors, Glucocorticoid metabolism, Fatty Liver, Alcoholic metabolism, Transcriptome
- Abstract
Patients with severe alcoholic hepatitis (SAH) not responding to glucocorticoid therapy have higher mortality, though they do not differ in their baseline clinical characteristics and prognostic scores from those who respond to therapy. We hypothesized that the baseline hepatic gene expression differs between responders (R) and non-responders (NR). Baseline liver transcriptome was compared between R and NR in Indian (16 each) and French (5 NR, 3 R) patients with SAH. There were differentially expressed genes (DEGs) between NR and R, in Indian (1106 over-expressed, 96 under-expressed genes) and French patients (65 over-expressed, 142 under-expressed genes). Indian NR had features of hepatocyte senescence and French NR exhibited under-expression of genes involved in cell division, indicating a central defect in the capacity of hepatocytes for self-renewal in both populations. Markers of hepatic progenitor cell proliferation were either very few (Indian patients) or absent (French patients). No DEGs were enriched in inflammatory pathways and there were no differences in nuclear receptor subfamily 3 group C member 1 (NR3C1) transcript expression and splicing between NR and R. Our results reveal that baseline hepatic transcriptome is reflective of subsequent glucocorticoid non-response and indicate impaired regenerative potential of the liver as an underlying phenomenon in NR.
- Published
- 2017
- Full Text
- View/download PDF
25. Autophagy in chronic liver diseases: the two faces of Janus.
- Author
-
Gual P, Gilgenkrantz H, and Lotersztajn S
- Subjects
- Evidence-Based Medicine, Humans, Liver pathology, Models, Biological, Autophagy, End Stage Liver Disease pathology, End Stage Liver Disease physiopathology, Fatty Liver pathology, Fatty Liver physiopathology, Liver physiopathology
- Abstract
Alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are the leading causes of cirrhosis and increase the risk of hepatocellular carcinoma and liver-related death. ALD and NAFLD share common pathogenic features extending from isolated steatosis to steatohepatitis and steatofibrosis, which can progress to cirrhosis and hepatocellular carcinoma. The pathophysiological mechanisms of the progression of NAFLD and ALD are complex and still unclear. Important links between the regulation of autophagy (macroautophagy and chaperone-mediated autophagy) and chronic liver diseases have been reported. Autophagy may protect against steatosis and progression to steatohepatitis by limiting hepatocyte injury and reducing M1 polarization, as well as promoting liver regeneration. Its role in fibrosis and hepatocarcinogenesis is more complex. It has pro- and antifibrogenic properties depending on the hepatic cell type concerned, and beneficial and deleterious effects on hepatocarcinogenesis at initiating and late phases, respectively. This review summarizes the latest advances on the role of autophagy in different stages of fatty liver disease progression and describes its divergent and cell-specific effects during chronic liver injury., (Copyright © 2017 the American Physiological Society.)
- Published
- 2017
- Full Text
- View/download PDF
26. LKB1 and Notch Pathways Interact and Control Biliary Morphogenesis.
- Author
-
Just PA, Poncy A, Charawi S, Dahmani R, Traore M, Dumontet T, Drouet V, Dumont F, Gilgenkrantz H, Colnot S, Terris B, Coulouarn C, Lemaigre F, and Perret C
- Subjects
- AMP-Activated Protein Kinase Kinases, AMP-Activated Protein Kinases, Animals, Bile Duct Neoplasms metabolism, Bile Duct Neoplasms pathology, Bile Ducts metabolism, Cell Line, Tumor, Cholangiocarcinoma metabolism, Cholangiocarcinoma pathology, Cholestasis genetics, Cholestasis pathology, Humans, Immunoglobulin J Recombination Signal Sequence-Binding Protein genetics, Immunoglobulin J Recombination Signal Sequence-Binding Protein metabolism, Liver embryology, Mice, Transgenic, Morphogenesis, Protein Serine-Threonine Kinases genetics, Receptors, Notch genetics, Bile Ducts embryology, Protein Serine-Threonine Kinases metabolism, Receptors, Notch metabolism
- Abstract
Background: LKB1 is an evolutionary conserved kinase implicated in a wide range of cellular functions including inhibition of cell proliferation, regulation of cell polarity and metabolism. When Lkb1 is inactivated in the liver, glucose homeostasis is perturbed, cellular polarity is affected and cholestasis develops. Cholestasis occurs as a result from deficient bile duct development, yet how LKB1 impacts on biliary morphogenesis is unknown., Methodology/principal Findings: We characterized the phenotype of mice in which deletion of the Lkb1 gene has been specifically targeted to the hepatoblasts. Our results confirmed that lack of LKB1 in the liver results in bile duct paucity leading to cholestasis. Immunostaining analysis at a prenatal stage showed that LKB1 is not required for differentiation of hepatoblasts to cholangiocyte precursors but promotes maturation of the primitive ductal structures to mature bile ducts. This phenotype is similar to that obtained upon inactivation of Notch signaling in the liver. We tested the hypothesis of a functional overlap between the LKB1 and Notch pathways by gene expression profiling of livers deficient in Lkb1 or in the Notch mediator RbpJκ and identified a mutual cross-talk between LKB1 and Notch signaling. In vitro experiments confirmed that Notch activity was deficient upon LKB1 loss., Conclusion: LKB1 and Notch share a common genetic program in the liver, and regulate bile duct morphogenesis.
- Published
- 2015
- Full Text
- View/download PDF
27. Bile acids and FGF receptors: orchestrators of optimal liver regeneration.
- Author
-
Gilgenkrantz H and Tordjmann T
- Subjects
- Animals, Biomarkers metabolism, Cell Proliferation physiology, Hepatectomy methods, Hepatocytes cytology, Humans, Mice, Receptors, Fibroblast Growth Factor genetics, Recovery of Function, Sensitivity and Specificity, Bile Acids and Salts metabolism, Hepatocytes physiology, Liver Regeneration physiology, Receptors, Fibroblast Growth Factor metabolism
- Published
- 2015
- Full Text
- View/download PDF
28. GH administration rescues fatty liver regeneration impairment by restoring GH/EGFR pathway deficiency.
- Author
-
Collin de l'Hortet A, Zerrad-Saadi A, Prip-Buus C, Fauveau V, Helmy N, Ziol M, Vons C, Billot K, Baud V, Gilgenkrantz H, and Guidotti JE
- Subjects
- Animals, Blotting, Western, Cell Proliferation drug effects, Choline metabolism, Diet, Down-Regulation drug effects, ErbB Receptors genetics, Fatty Liver metabolism, Fatty Liver physiopathology, Hepatectomy methods, Hepatocytes drug effects, Hepatocytes metabolism, Hepatocytes pathology, Human Growth Hormone blood, Human Growth Hormone deficiency, Humans, Liver drug effects, Liver metabolism, Liver surgery, Male, Methionine metabolism, Mice, Mice, Inbred C57BL, Mice, Obese, Non-alcoholic Fatty Liver Disease, Obesity metabolism, Obesity physiopathology, Reverse Transcriptase Polymerase Chain Reaction, STAT3 Transcription Factor metabolism, Signal Transduction genetics, Signal Transduction physiology, Triglycerides metabolism, ErbB Receptors metabolism, Fatty Liver prevention & control, Human Growth Hormone administration & dosage, Signal Transduction drug effects
- Abstract
GH pathway has been shown to play a major role in liver regeneration through the control of epidermal growth factor receptor (EGFR) activation. This pathway is down-regulated in nonalcoholic fatty liver disease. Because regeneration is known to be impaired in fatty livers, we wondered whether a deregulation of the GH/EGFR pathway could explain this deficiency. Hepatic EGFR expression and triglyceride levels were quantified in liver biopsies of 32 obese patients with different degrees of steatosis. We showed a significant inverse correlation between liver EGFR expression and the level of hepatic steatosis. GH/EGFR down-regulation was also demonstrated in 2 steatosis mouse models, a genetic (ob/ob) and a methionine and choline-deficient diet mouse model, in correlation with liver regeneration defect. ob/ob mice exhibited a more severe liver regeneration defect after partial hepatectomy (PH) than methionine and choline-deficient diet-fed mice, a difference that could be explained by a decrease in signal transducer and activator of transcription 3 phosphorylation 32 hours after PH. Having checked that GH deficiency accounted for the GH signaling pathway down-regulation in the liver of ob/ob mice, we showed that GH administration in these mice led to a partial rescue in hepatocyte proliferation after PH associated with a concomitant restoration of liver EGFR expression and signal transducer and activator of trnascription 3 activation. In conclusion, we propose that the GH/EGFR pathway down-regulation is a general mechanism responsible for liver regeneration deficiency associated with steatosis, which could be partially rescued by GH administration.
- Published
- 2014
- Full Text
- View/download PDF
29. Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFβ signaling pathways.
- Author
-
Coulouarn C, Cavard C, Rubbia-Brandt L, Audebourg A, Dumont F, Jacques S, Just PA, Clément B, Gilgenkrantz H, Perret C, and Terris B
- Subjects
- Bile Duct Neoplasms, Bile Ducts, Intrahepatic, Carcinoma, Hepatocellular pathology, Cell Differentiation, Cholangiocarcinoma pathology, Extracellular Matrix physiology, Gene Expression Profiling, Humans, Liver Neoplasms pathology, Prognosis, Signal Transduction physiology, Tissue Array Analysis, beta Catenin physiology, Carcinoma, Hepatocellular etiology, Cholangiocarcinoma etiology, Liver Neoplasms etiology, Neoplastic Stem Cells pathology, Transforming Growth Factor beta physiology, Wnt Signaling Pathway physiology
- Abstract
Intrahepatic malignant tumours include hepatocellular carcinomas (HCC), cholangiocarcinomas (CC) and combined hepatocholangiocarcinomas (cHCC-CC), a group of rare and poorly characterized tumours that exhibit both biliary and hepatocytic differentiation. The aim of the study was to characterize the molecular pathways specifically associated with cHCC-CC pathogenesis. We performed a genome-wide transcriptional analysis of 20 histologically defined cHCC-CC and compared them with a series of typical HCC and of CC. Data were analysed by gene set enrichment and integrative genomics and results were further validated in situ by tissue microarray using an independent series of 152 tumours. We report that cHCC-CC exhibit stem/progenitor features, a down-regulation of the hepatocyte differentiation program and a commitment to the biliary lineage. TGFβ and Wnt/β-catenin were identified as the two major signalling pathways activated in cHCC-CC. A β-catenin signature distinct from that observed in well-differentiated HCC with mutant β-catenin was found in cHCC-CC. This signature was associated with microenvironment remodelling and TGFβ activation. Furthermore, integrative genomics revealed that cHCC-CC share characteristics of poorly differentiated HCC with stem cell traits and poor prognosis. The common traits displayed by CC, cHCC-CC and some HCC suggest that these tumours could originate from stem/progenitor cell(s) and raised the hypothesis of a potential continuum between intrahepatic CC, cHCC-CC and poorly differentiated HCC.
- Published
- 2012
- Full Text
- View/download PDF
30. EGFR: A Master Piece in G1/S Phase Transition of Liver Regeneration.
- Author
-
Collin de L'hortet A, Gilgenkrantz H, and Guidotti JE
- Abstract
Unraveling the molecular clues of liver proliferation has become conceivable thanks to the model of two-third hepatectomy. The synchronicity and the well-scheduled aspect of this process allow scientists to slowly decipher this mystery. During this phenomenon, quiescent hepatocytes of the remnant lobes are able to reenter into the cell cycle initiating the G1-S progression synchronously before completing the cell cycle. The major role played by this step of the cell cycle has been emphasized by loss-of-function studies showing a delay or a lack of coordination in the hepatocytes G1-S progression. Two growth factor receptors, c-Met and EGFR, tightly drive this transition. Due to the level of complexity surrounding EGFR signaling, involving numerous ligands, highly controlled regulations and multiple downstream pathways, we chose to focus on the EGFR pathway for this paper. We will first describe the EGFR pathway in its integrity and then address its essential role in the G1/S phase transition for hepatocyte proliferation. Recently, other levels of control have been discovered to monitor this pathway, which will lead us to discuss regulations of the EGFR pathway and highlight the potential effect of misregulations in pathologies.
- Published
- 2012
- Full Text
- View/download PDF
31. Increased susceptibility to liver fibrosis with age is correlated with an altered inflammatory response.
- Author
-
Mahrouf-Yorgov M, Collin de l'Hortet A, Cosson C, Slama A, Abdoun E, Guidotti JE, Fromenty B, Mitchell C, and Gilgenkrantz H
- Subjects
- Animals, Carbon Tetrachloride, Cell Proliferation, Chronic Disease, Hepatocytes pathology, Humans, Male, Mice, Mice, Inbred C57BL, Necrosis, Oxidative Stress, Aging pathology, Disease Susceptibility, Inflammation complications, Inflammation pathology, Liver Cirrhosis complications, Liver Cirrhosis pathology
- Abstract
It has been suggested that increasing age is correlated with an acceleration of the progression of liver fibrosis induced by various agents, such as hepatitis C virus or chronic alcohol consumption. However, the cellular and molecular changes underlying this predisposition are not entirely understood. In the context of an aging population, it becomes challenging to decipher the mechanisms responsible for this higher susceptibility of older individuals to this acquired liver disorder. To address this issue, we induced liver fibrosis by carbon tetrachloride (CCl(4)) chronic administration to 8-week- and 15-month-old mice. We confirmed that susceptibility to fibrosis development increased with age and showed that aging did not affect fibrosis resolution capacity. We then focused on the impairment of hepatocyte proliferation, oxidative stress, and inflammation as potential mechanisms accelerating the development of fibrosis in the elderly. We detected no inhibition of hepatocyte proliferation after CCl(4) injury in 15-month-old mice, whereas it was inhibited after a partial hepatectomy. Finally, we observed that, in a context in which liver oxidative stress was not differentially increased in both experimental groups, there was a higher recruitment of inflammatory cells, including mostly macrophages and lymphocytes, oriented toward a T helper 2 (T(H)2) response in older mice. Our data show that in conditions of equivalent levels of oxidative stress and maintained hepatocyte proliferative capacity, an increased inflammatory reaction mainly composed of CD4(+) lymphocytes and macrophages expressing T(H)2 cytokines is the main factor involved in the higher susceptibility to fibrosis with increasing age.
- Published
- 2011
- Full Text
- View/download PDF
32. GH receptor plays a major role in liver regeneration through the control of EGFR and ERK1/2 activation.
- Author
-
Zerrad-Saadi A, Lambert-Blot M, Mitchell C, Bretes H, Collin de l'Hortet A, Baud V, Chereau F, Sotiropoulos A, Kopchick JJ, Liao L, Xu J, Gilgenkrantz H, and Guidotti JE
- Subjects
- Animals, Crosses, Genetic, Enzyme Activation, Enzyme Induction, ErbB Receptors genetics, G1 Phase, Insulin-Like Growth Factor I genetics, Insulin-Like Growth Factor I metabolism, Liver cytology, Male, Mice, Mice, Knockout, Mice, Transgenic, Phosphorylation, Protein Processing, Post-Translational, RNA, Messenger metabolism, Receptors, Somatotropin genetics, ErbB Receptors metabolism, Liver physiology, Liver Regeneration, Mitogen-Activated Protein Kinase 1 metabolism, Mitogen-Activated Protein Kinase 3 metabolism, Receptors, Somatotropin physiology, Signal Transduction
- Abstract
GH is a pleiotropic hormone that plays a major role in proliferation, differentiation, and metabolism via its specific receptor. It has been previously suggested that GH signaling pathways are required for normal liver regeneration but the molecular mechanisms involved have yet to be determined. The aim of this study was to identify the mechanisms by which GH controls liver regeneration. We performed two thirds partial hepatectomies in GH receptor (GHR)-deficient mice and wild-type littermates and showed a blunted progression in the G(1)/S transition phase of the mutant hepatocytes. This impaired liver regeneration was not corrected by reestablishing IGF-1 expression. Although the initial response to partial hepatectomy at the priming phase appeared to be similar between mutant and wild-type mice, cell cycle progression was significantly blunted in mutant mice. The main defect in GHR-deficient mice was the deficiency of the epidermal growth factor receptor activation during the process of liver regeneration. Finally, among the pathways activated downstream of GHR during G(1) phase progression, namely Erk1/2, Akt, and signal transducer and activator of transcription 3, we only found a reduced Erk1/2 phosphorylation in mutant mice. In conclusion, our results demonstrate that GH signaling plays a major role in liver regeneration and strongly suggest that it acts through the activation of both epidermal growth factor receptor and Erk1/2 pathways.
- Published
- 2011
- Full Text
- View/download PDF
33. Transient micro-elastography: A novel non-invasive approach to measure liver stiffness in mice.
- Author
-
Bastard C, Bosisio MR, Chabert M, Kalopissis AD, Mahrouf-Yorgov M, Gilgenkrantz H, Mueller S, and Sandrin L
- Subjects
- Amyloidosis chemically induced, Amyloidosis pathology, Animals, Carbon Tetrachloride toxicity, Female, Liver drug effects, Male, Mice, Mice, Inbred Strains, Elasticity Imaging Techniques methods, Liver pathology
- Abstract
Aim: To develop and validate a transient micro-elastography device to measure liver stiffness (LS) in mice., Methods: A novel transient micro-elastography (TME) device, dedicated to LS measurements in mice with a range of measurement from 1-170 kPa, was developed using an optimized vibration frequency of 300 Hz and a 2 mm piston. The novel probe was validated in a classical fibrosis model (CCl(4)) and in a transgenic murine model of systemic amyloidosis., Results: TME could be successfully performed in control mice below the xiphoid cartilage, with a mean LS of 4.4 ± 1.3 kPa, a mean success rate of 88%, and an excellent intra-observer agreement (0.98). Treatment with CCl(4) over seven weeks drastically increased LS as compared to controls (18.2 ± 3.7 kPa vs 3.6 ± 1.2 kPa). Moreover, fibrosis stage was highly correlated with LS (Spearman coefficient = 0.88, P < 0.01). In the amyloidosis model, much higher LS values were obtained, reaching maximum values of > 150 kPa. LS significantly correlated with the amyloidosis index (0.93, P < 0.0001) and the plasma concentration of mutant hapoA-II (0.62, P < 0.005)., Conclusion: Here, we have established the first non-invasive approach to measure LS in mice, and have successfully validated it in two murine models of high LS.
- Published
- 2011
- Full Text
- View/download PDF
34. Overexpression of Bcl-2 in hepatocytes protects against injury but does not attenuate fibrosis in a mouse model of chronic cholestatic liver disease.
- Author
-
Mitchell C, Mahrouf-Yorgov M, Mayeuf A, Robin MA, Mansouri A, Fromenty B, and Gilgenkrantz H
- Subjects
- Animals, Bile Ducts surgery, Blotting, Western, Caspases metabolism, Electron Transport Complex I metabolism, Histological Techniques, In Situ Nick-End Labeling, Ligation, Lipid Peroxidation physiology, Mice, Mice, Transgenic, Reverse Transcriptase Polymerase Chain Reaction, Apoptosis physiology, Cholestasis, Intrahepatic metabolism, Hepatocytes metabolism, Necrosis physiopathology, Proto-Oncogene Proteins c-bcl-2 metabolism
- Abstract
The role of hepatocyte apoptosis in the physiopathology of obstructive cholestasis is still controversial. Although some data have strongly suggested that hepatocellular cholestatic injury is due to Fas-mediated hepatocyte apoptosis, some others concluded that necrosis, rather than apoptosis, represents the main type of hepatocyte death in chronic cholestasis. Moreover, it has also been suggested that the reduced liver injury observed in the absence of Fas receptor after bile duct ligation was not due to lower hepatocyte apoptosis but to the indirect role of this receptor in non-hepatocytic cells such as cholangiocytes and inflammatory cells. The aim of this work was therefore to determine whether a protection against cell death limited to hepatocytes could be sufficient to reduce liver injury and delay cholestatic fibrosis. With this purpose, we performed bile duct ligation in transgenic mice overexpressing Bcl-2 in hepatocytes and in wild-type littermates. We found that, compared with necrosis, apoptosis was negligible in this model. Our results also showed that hepatocyte Bcl-2 expression protected hepatocytes against liver injury only in the early steps of the disease. This protection was correlated with reduced mitochondrial dysfunction and lipid peroxidation. However, in contrast to Fas receptor-deficient lpr mice, fibrosis progression was not hampered and liver inflammatory response was not reduced by Bcl-2 overexpression. These results therefore comfort the hypothesis that Fas-mediated apoptotic hepatocyte pathway is not a significant contributing factor to the clinical features observed in cholestasis. Moreover, in the absence of a blunted inflammatory response in transgenic mice, Bcl-2 protection against hepatocyte mitochondrial dysfunction and lipid peroxidation was not sufficient to block fibrosis progression.
- Published
- 2011
- Full Text
- View/download PDF
35. Rodent models of liver repopulation.
- Author
-
Gilgenkrantz H
- Subjects
- Animals, Hepatocytes cytology, Humans, Liver cytology, Mice, Models, Animal, Stem Cells cytology, Hepatocytes transplantation, Liver Regeneration
- Abstract
The liver has an extraordinary faculty to regenerate. Hepatocytes are highly differentiated cells that, despite a resting G0 state in the normal quiescent liver, can re-enter the cell cycle to reconstitute the organ after an injury. However, the first cell therapy approaches trying to harness this specific characteristic of the hepatocytes came up against the competition with resident hepatocytes in the ability to proliferate. This review will describe the different rodent models that have been developed in the last 15 years to demonstrate the concept of liver repopulation with transplanted cells harbouring a selective advantage over resident hepatocytes. Examples will then be given to show how these models demonstrated the therapeutic efficiency of cell transplantation in specific disorders. The transplantation of human hepatocytes into some of these mouse models led to the creation of humanized livers. These humanized mice provide a powerful tool to study the physiopathology of human hepatotropic pathogens and to develop drugs against them. Finally, emphasis will be placed on the role of these rodent models in the demonstration of the hepatocytic potential of stem cells.
- Published
- 2010
- Full Text
- View/download PDF
36. Protection against hepatocyte mitochondrial dysfunction delays fibrosis progression in mice.
- Author
-
Mitchell C, Robin MA, Mayeuf A, Mahrouf-Yorgov M, Mansouri A, Hamard M, Couton D, Fromenty B, and Gilgenkrantz H
- Subjects
- Animals, Apoptosis drug effects, Biomarkers metabolism, Carbon Tetrachloride toxicity, Caspases metabolism, Disease Progression, Fibrosis metabolism, Fibrosis pathology, Fibrosis physiopathology, Hepatocytes drug effects, Hepatocytes physiology, Lipid Peroxidation, Male, Mice, Mice, Inbred C57BL, Mice, Transgenic, Oxidative Stress, Proto-Oncogene Proteins c-bcl-2 genetics, Proto-Oncogene Proteins c-bcl-2 metabolism, Hepatocytes cytology, Hepatocytes pathology, Mitochondria, Liver drug effects, Mitochondria, Liver metabolism, Mitochondria, Liver pathology
- Abstract
Accumulating evidence indicates that oxidative stress is involved in the physiopathology of liver fibrogenesis. However, amid the global context of hepatic oxidative stress, the specific role of hepatocyte mitochondrial dysfunction in the fibrogenic process is still unknown. The aim of this study was to determine whether a targeted protection of hepatocytes against mitochondrial dysfunction could modulate fibrosis progression. We induced liver fibrogenesis by chronic carbon tetrachloride treatment (3 or 6 weeks of biweekly injections) in transgenic mice expressing Bcl-2 in their hepatocytes or in normal control mice. Analyses of mitochondrial DNA, respiratory chain complexes, and lipid peroxidation showed that Bcl-2 transgenic animals were protected against mitochondrial dysfunction and oxidative stress resulting from carbon tetrachloride injury. Picrosirius red staining, alpha-smooth muscle actin immunohistochemistry, and real-time PCR for transforming growth factor-beta and collagen alpha-I revealed that Bcl-2 transgenic mice presented reduced fibrosis at early stages of fibrogenesis. However, at later stages increased nonmitochondrial/nonhepatocytic oxidative stress eventually overcame the capacity of Bcl-2 overexpression to prevent the fibrotic process. In conclusion, we demonstrate for the first time that specific protection against hepatocyte mitochondrial dysfunction plays a preventive role in early stages of fibrogenesis, delaying its onset. However, with the persistence of the aggression, this protection is no longer sufficient to impede fibrosis progression.
- Published
- 2009
- Full Text
- View/download PDF
37. Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice.
- Author
-
Mitchell C, Couton D, Couty JP, Anson M, Crain AM, Bizet V, Rénia L, Pol S, Mallet V, and Gilgenkrantz H
- Subjects
- Animals, Blotting, Western, CD11b Antigen metabolism, CD11c Antigen metabolism, Carbon Tetrachloride toxicity, Flow Cytometry, Immunoenzyme Techniques, Liver drug effects, Liver injuries, Liver metabolism, Liver Cirrhosis chemically induced, Macrophages cytology, Macrophages drug effects, Macrophages metabolism, Matrix Metalloproteinase 13 metabolism, Matrix Metalloproteinase 2 metabolism, Mice, Mice, Inbred BALB C, Mice, Knockout, RNA, Messenger genetics, RNA, Messenger metabolism, Reverse Transcriptase Polymerase Chain Reaction, Tissue Inhibitor of Metalloproteinase-1 genetics, Tissue Inhibitor of Metalloproteinase-1 metabolism, Liver Cirrhosis metabolism, Liver Cirrhosis pathology, Receptors, CCR2 physiology
- Abstract
Inflammation has been shown to induce the progression of fibrosis in response to liver injury. Among inflammatory cells, macrophages and lymphocytes play major roles in both the constitution and resolution of liver fibrosis. The chemokine receptor CCR2 is involved in the recruitment of monocytes to injury sites, and it is known to be induced during the progression of fibrosis in humans. However, its specific role during this process has not yet been unveiled. We first demonstrated that, compared with wild-type mice, CCR2 knockout animals presented a delay in liver injury after acute CCl(4) injection, accompanied by a reduction in infiltrating macrophage populations. We then induced fibrosis using repeated injections of CCl(4) and observed a significantly lower level of fibrotic scars at the peak of fibrosis in mutant animals compared with control mice. This diminished fibrosis was associated with a reduction in F4/80(+)CD11b(+) and CD11c(+) populations at the sites of injury. Subsequent analysis of the kinetics of the resolution of fibrosis showed that fibrosis rapidly regressed in wild-type, but not in CCR2(-/-) mice. The persistence of hepatic injury in mutant animals was correlated with sustained tissue inhibitor of metalloproteinase-1 mRNA expression levels and a reduction in matrix metalloproteinase-2 and matrix metalloproteinase-13 expression levels. In conclusion, these findings underline the role of the CCR2 signaling pathway in both the constitution and resolution of liver fibrotic scars.
- Published
- 2009
- Full Text
- View/download PDF
38. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C.
- Author
-
Mallet V, Gilgenkrantz H, Serpaggi J, Verkarre V, Vallet-Pichard A, Fontaine H, and Pol S
- Subjects
- Biopsy, Follow-Up Studies, Humans, Retrospective Studies, Antiviral Agents therapeutic use, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic pathology, Interferons therapeutic use, Liver Cirrhosis pathology
- Abstract
Background: The effect of regression of cirrhosis in chronic hepatitis C is unknown., Objective: To evaluate the relation between regression of cirrhosis and clinical outcome in patients with chronic hepatitis C after antiviral therapy., Design: A cohort of patients with cirrhosis treated between 1988 and 2001., Setting: Hepatology unit of a tertiary care center in France., Patients: 96 patients with chronic hepatitis C and biopsy-proven cirrhosis (METAVIR score F4) who were treated with an interferon-based regimen and had at least 1 posttreatment liver biopsy. Patients were followed until November 2006., Measurements: Occurrence of a combined end point of liver-related events (ascites, hepatic encephalopathy, variceal bleeding, spontaneous bacterial peritonitis, hepatocellular carcinoma, or liver transplantation) and death in patients with regression of cirrhosis (defined as a decrease from 4 to
- Published
- 2008
- Full Text
- View/download PDF
39. Had Prometheus known, would he have preferred to be obese?
- Author
-
Mitchell C and Gilgenkrantz H
- Subjects
- Animals, Cell Cycle, Disease Models, Animal, Fatty Liver complications, Fatty Liver mortality, Humans, Liver Regeneration, Mice, Obesity complications, Obesity pathology
- Published
- 2007
- Full Text
- View/download PDF
40. Transplanted hepatocytes over-expressing FoxM1B efficiently repopulate chronically injured mouse liver independent of donor age.
- Author
-
Brezillon N, Lambert-Blot M, Morosan S, Couton D, Mitchell C, Kremsdorf D, Costa RH, Gilgenkrantz H, and Guidotti JE
- Subjects
- Age Factors, Animals, Cell Proliferation, Female, Forkhead Box Protein M1, Forkhead Transcription Factors physiology, Hepatocytes cytology, Liver injuries, Liver metabolism, Male, Mice, Mice, SCID, Mice, Transgenic, Transplantation, Homologous methods, Forkhead Transcription Factors genetics, Hepatocytes metabolism, Hepatocytes transplantation, Liver surgery
- Abstract
Orthotopic liver transplantation is limited by the shortage of liver donors, leading to elderly patients being enrolled as donors with increasing frequency. Alternative strategies such as cell therapy are therefore needed. Because transplanted hepatocytes do not proliferate into a recipient liver, repopulation strategies have been developed. We have previously published a proof of concept that hepatocytes harboring a survival selective advantage can efficiently repopulate a mouse liver. We develop here an alternative approach by conferring a selective proliferative advantage on transplanted hepatocytes over resident ones. FoxM1B is a transcription factor that, when over-expressed into hepatocytes, accelerates the cell cycle and maintains the hepatocyte in vivo proliferative capacity of aged livers. We now demonstrate that transplanted hepatocytes over-expressing FoxM1B repopulate the liver of mice subjected to continuous injury far more efficiently than control hepatocytes. We show that old hepatocytes that over-express FoxM1B retain their cell division capacity and repopulate liver as well as young ones, in contrast with old non-modified hepatocytes, which lose their proliferative capacity. In conclusion, our results point to the potential use of FoxM1B expression in hepatocyte-based therapy protocols in diseases where host hepatocytes are chronically injured, especially if donor hepatocytes come from old livers.
- Published
- 2007
- Full Text
- View/download PDF
41. Delayed liver regeneration in mice lacking liver serum response factor.
- Author
-
Latasa MU, Couton D, Charvet C, Lafanechère A, Guidotti JE, Li Z, Tuil D, Daegelen D, Mitchell C, and Gilgenkrantz H
- Subjects
- Animals, Cell Cycle, Cell Cycle Proteins genetics, Cell Cycle Proteins metabolism, Cell Proliferation, DNA biosynthesis, Hepatectomy, Immediate-Early Proteins genetics, Immediate-Early Proteins metabolism, Liver cytology, Liver physiology, Liver surgery, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Knockout, RNA, Messenger metabolism, Serum Response Factor deficiency, Serum Response Factor genetics, Time Factors, Transcriptional Activation, Liver metabolism, Liver Regeneration genetics, Serum Response Factor metabolism
- Abstract
Various immediate early genes (IEGs) upregulated during the early process of liver regeneration are transcriptional targets of the serum response factor (SRF). We show here that the expression of SRF is rapidly induced in rodent liver after partial hepatectomy. Because the inactivation of the SRF gene in mice is embryonic lethal, the in vivo role of SRF in liver regeneration after partial hepatectomy was analyzed in mutant mice conditionally deleted for SRF in the liver. We demonstrate that SRF is not an essential factor for liver ontogenesis. However, adult mutant mice show impaired liver regeneration after partial hepatectomy, associated with a blunted upregulation of various SRF target IEGs. In conclusion, our work suggests that SRF is an early response transcription factor that may contribute to the initial phases of liver regeneration through its activation of IEGs.
- Published
- 2007
- Full Text
- View/download PDF
42. Conditional inactivation of the murine serum response factor in the pancreas leads to severe pancreatitis.
- Author
-
Miralles F, Hebrard S, Lamotte L, Durel B, Gilgenkrantz H, Li Z, Daegelen D, Tuil D, and Joshi RL
- Subjects
- Animals, Disease Models, Animal, Islets of Langerhans physiology, Mice, Mice, Transgenic, NF-kappa B metabolism, Pancreas, Exocrine pathology, Pancreatitis immunology, Pancreatitis pathology, Pancreas, Exocrine physiopathology, Pancreatitis physiopathology, Serum Response Factor genetics, Serum Response Factor physiology
- Abstract
The Serum Response Factor (SRF) is widely expressed transcription factor acting at the confluence of multiple signaling pathways and has been implicated in the control of differentiation, growth, and cell death. In the present study, we found that SRF is expressed in the developing and adult pancreas. To explore the possible role of SRF in this organ, we have generated mutant mice with conditional disruption of the Srf gene. Such mutants presented normal development of both the exocrine and endocrine pancreas indicating that SRF is dispensable for pancreas ontogenesis. However, after weaning, these mice developed profound morphological alterations of the exocrine pancreas, which were reminiscent of severe pancreatitis. In these mice, massive acinar injury, Nuclear Factor Kappa B activation and proinflammatory cytokines release led to complete destruction of the exocrine pancreas and its replacement by adipose tissue. Despite these changes, the organization and function of the endocrine islets of Langerhans remained well-preserved. This new animal model of spontaneous pancreatitis could prove a valuable tool to gain further insight into the physiopathology of this disease.
- Published
- 2006
- Full Text
- View/download PDF
43. Mobilizing stem cells to repair liver after surgery: dream or reality?
- Author
-
Mallet VO and Gilgenkrantz H
- Subjects
- AC133 Antigen, Animals, Antigens, CD genetics, Antigens, CD metabolism, Glycoproteins genetics, Glycoproteins metabolism, Hepatectomy, Humans, Mice, Mice, Knockout, Peptides genetics, Peptides metabolism, Stem Cells cytology, Liver cytology, Liver pathology, Liver physiology, Liver surgery, Liver Regeneration, Stem Cells physiology
- Published
- 2005
- Full Text
- View/download PDF
44. Mesenchymal stem cells: an alternative source of hepatocytes?
- Author
-
Gilgenkrantz H
- Subjects
- Animals, Humans, Hepatocytes cytology, Mesoderm cytology, Stem Cells cytology
- Published
- 2004
- Full Text
- View/download PDF
45. A highly efficient, stable, and rapid approach for ex vivo human liver gene therapy via a FLAP lentiviral vector.
- Author
-
Giannini C, Morosan S, Tralhao JG, Guidotti JE, Battaglia S, Mollier K, Hannoun L, Kremsdorf D, Gilgenkrantz H, and Charneau P
- Subjects
- Animals, Cell Differentiation, Cell Division, Cells, Cultured, Hepatocytes physiology, Hepatocytes transplantation, Humans, Mice, Mice, SCID, Phenotype, Rats, Transduction, Genetic, Transgenes genetics, Genetic Therapy methods, Genetic Vectors, Hepatocytes cytology, Lentivirus genetics
- Abstract
Allogenic hepatocyte transplantation or autologous transplantation of genetically modified hepatocytes has been used successfully to correct congenital or acquired liver diseases and can be considered as an alternative to orthotopic liver transplantation. However, hepatocytes are neither easily maintained in culture nor efficiently genetically modified and are very sensitive to dissociation before their reimplantation into the recipient. These difficulties have greatly limited the use of an ex vivo approach in clinical trials. In the present study, we have shown that primary human and rat hepatocytes can be efficiently transduced with a FLAP lentiviral vector without the need for plating and culture. Efficient transduction of nonadherent primary hepatocytes was achieved with a short period of contact with vector particles, without modifying hepatocyte viability, and using reduced amounts of vector. We also showed that the presence of the DNA FLAP in the vector construct was essential to reach high levels of transduction. Moreover, transplanted into uPA/SCID mouse liver, lentivirally transduced primary human hepatocytes extensively repopulated their liver and maintained a differentiated and functional phenotype as assessed by the stable detection of human albumin and antitrypsin in the serum of the animals for months. In conclusion, the use of FLAP lentiviral vectors allows, in a short period of time, a high transduction efficiency of human functional and reimplantable hepatocytes. This work therefore opens new perspectives for the development of human clinical trials based on liver-directed ex vivo gene therapy.
- Published
- 2003
- Full Text
- View/download PDF
46. Conditional cell ablation by tight control of caspase-3 dimerization in transgenic mice.
- Author
-
Mallet VO, Mitchell C, Guidotti JE, Jaffray P, Fabre M, Spencer D, Arnoult D, Kahn A, and Gilgenkrantz H
- Subjects
- Animals, Apoptosis drug effects, Caspase 3, Caspases genetics, Cell Line, Dimerization, Dose-Response Relationship, Drug, Enzyme Activation, Gene Expression Regulation drug effects, Hepatocytes cytology, Hepatocytes drug effects, Humans, Injections, Intraperitoneal, Liver Regeneration drug effects, Liver Regeneration physiology, Macromolecular Substances, Mice, Mice, Transgenic, Monitoring, Intraoperative, Recombinant Fusion Proteins genetics, Recombinant Fusion Proteins metabolism, Reference Values, Apoptosis physiology, Caspases metabolism, Gene Expression Regulation physiology, Hepatocytes physiology, Tacrolimus administration & dosage, Tacrolimus analogs & derivatives
- Abstract
Studying the effects of the loss of a specific cell type is a powerful approach in biology. Here we present a method based on the controlled activation of the apoptotic machinery. We expressed a modified caspase-3-containing chemical inducer of dimerization (CID)-binding sites in the livers of transgenic mice. In the absence of CID, no liver injury was detectable, underlining the absence of leakage in our system. In contrast, injection of the CID produced activation of the chimeric caspase-3, which led to a dose-dependent pure hepatocyte ablation with subsequent regeneration. This method is effective in both growing and nongrowing cells, and is therefore applicable to a wide range of cells and tissues. Moreover, because apoptosis has been described in numerous pathological circumstances, this system is useful for generating mouse models of human disorders as well as for studying the recovery or regeneration of tissues after cell loss.
- Published
- 2002
- Full Text
- View/download PDF
47. In vivo electrotransfer of the cardiotrophin-1 gene into skeletal muscle slows down progression of motor neuron degeneration in pmn mice.
- Author
-
Lesbordes JC, Bordet T, Haase G, Castelnau-Ptakhine L, Rouhani S, Gilgenkrantz H, and Kahn A
- Subjects
- Animals, Animals, Newborn, Body Weight genetics, Cytokines metabolism, Dose-Response Relationship, Drug, Electroporation methods, Genetic Therapy methods, Mice, Mice, Neurologic Mutants, Motor Neuron Disease genetics, Motor Neuron Disease therapy, Motor Neurons drug effects, Motor Neurons physiology, Nerve Degeneration genetics, Nerve Degeneration therapy, Plasmids genetics, Plasmids pharmacology, Survival Rate, beta-Galactosidase genetics, Cytokines genetics, Gene Transfer Techniques, Motor Neurons pathology, Muscle, Skeletal physiology, Nerve Degeneration pathology
- Abstract
Among all vectors designed for gene therapy purposes, adenovirus appears to be the most efficient in vivo vehicle to transduce the broadest spectrum of cellular targets. However, the deleterious immunogenicity of this viral vector impedes its use in chronic diseases. Non-viral vectors, such as naked DNA, are attractive alternatives for safety and technical issues, such as scale-up production. Naked DNA injection, greatly improved when combined with electroporation, showed great potential in adult animals, especially when directed to the muscle. We have recently proven the therapeutic effect of a neonatal single intramuscular injection of a cardiotrophin-1 (CT-1)-encoding adenovirus in a hereditary disease mouse model of human motor neuron disease, the progressive motor neuronopathy (pmn) mutant. We now demonstrate that a single injection/electroporation of a CT-1-encoding plasmid in neonate pmn mice is almost as efficient as adenovirus-mediated gene transfer with respect to survival, muscular function and neuroprotection of the animals. Treated mice gain global weight, their mean lifespan is extended by 25%, all their electromyographic parameters are improved and myelinated axons of their phrenic nerves are protected. Moreover, we show that re-injection/electroporation leads to improvements in this neuroprotection. We therefore demonstrate for the first time the therapeutic efficacy of neonatal intramuscular DNA injection/electroporation in a murine model of a human hereditary disorder.
- Published
- 2002
- Full Text
- View/download PDF
48. The combination of ischemic preconditioning and liver Bcl-2 overexpression is a suitable strategy to prevent liver and lung damage after hepatic ischemia-reperfusion.
- Author
-
Peralta C, Perales JC, Bartrons R, Mitchell C, Gilgenkrantz H, Xaus C, Prats N, Fernández L, Gelpí E, Panés J, and Roselló-Catafau J
- Subjects
- Animals, Mice, Mice, Inbred CBA, Mice, Transgenic, Proto-Oncogene Proteins c-bcl-2 genetics, Ischemic Preconditioning, Liver pathology, Liver Circulation, Lung pathology, Proto-Oncogene Proteins c-bcl-2 biosynthesis, Pulmonary Circulation, Reperfusion Injury metabolism
- Abstract
The present study evaluates the effectiveness of ischemic preconditioning and Bcl-2 overexpression against the liver and lung damage that follow hepatic ischemia-reperfusion and investigates the underlying protective mechanisms. Preconditioning and Bcl-2, respectively, reduced the increased tumor necrosis factor (TNF) and macrophage inflammatory protein-2 (MIP)-2 levels observed after hepatic reperfusion. Bcl-2 overexpression or anti-MIP-2 pretreatment seems to be more effective than preconditioning or anti-TNF pretreatment against inflammatory response, microcirculatory disorders, and subsequent hepatic ischemia-reperfusion injury. Furthermore, each one of these strategies individually was unable to completely inhibit hepatic injury. The combination of preconditioning and Bcl-2 overexpression as well as the combined anti-TNF and anti-MIP-2 pretreatment totally prevented hepatic injury, whereas the benefits of preconditioning and Bcl-2 were abolished by TNF and MIP-2. In contrast to preconditioning, Bcl-2 did not modify lung damage induced by hepatic reperfusion. This could be explained by the differential effect of both treatments on TNF release. Anti-TNF therapy or preconditioning, by reducing TNF release, reduced pulmonary inflammatory response, whereas the benefits of preconditioning on lung damage were abolished by TNF. Thus, the induction of both Bcl-2 overexpression in liver and preconditioning, as well as pharmacological strategies that simulated their benefits, such as anti-TNF and anti-MIP-2 therapies, could be new strategies aimed to reduce lung damage and inhibit the hepatic injury associated with hepatic ischemia-reperfusion.
- Published
- 2002
- Full Text
- View/download PDF
49. Bone marrow transplantation in mice leads to a minor population of hepatocytes that can be selectively amplified in vivo.
- Author
-
Mallet VO, Mitchell C, Mezey E, Fabre M, Guidotti JE, Renia L, Coulombel L, Kahn A, and Gilgenkrantz H
- Subjects
- Animals, Cell Differentiation, Cell Division, Cellular Senescence, Hepatocytes physiology, Mice, Mice, Inbred C57BL, Mice, Transgenic genetics, Proto-Oncogene Proteins c-bcl-2 genetics, Proto-Oncogene Proteins c-bcl-2 metabolism, Bone Marrow Cells cytology, Bone Marrow Transplantation, Hepatocytes cytology
- Abstract
Cell-based therapy may some day be a therapeutic alternative to liver transplantation. Recent observations indicating that hematopoietic stem cells can differentiate into hepatocytes have opened new therapeutic prospects. However, the clinical relevance of this phenomenon is unknown. We have previously developed a strategy based on the protective effect of Bcl-2 against Fas-mediated apoptosis to selectively amplify a small number of hepatocytes in vivo. We now show that this approach can be used to amplify a minor population of bone marrow-derived hepatocytes. Normal mice were transplanted with unfractionated bone marrow cells from transgenic animals expressing Bcl-2 under the control of a liver-specific promoter. Recipients were then submitted to weekly injections of the anti-Fas antibody, Jo2. Upon sacrifice, the liver of the recipients showed bone marrow-derived clusters of mature hepatocytes expressing Bcl-2, which showed that the hepatocyte progeny of a genetically modified bone marrow can be selectively expanded in vivo. In contrast, no Bcl-2 expression could be detected without the selective pressure of Jo2, suggesting that differentiation of bone marrow cells into mature hepatocytes is very inefficient under physiologic conditions. We conclude that a selection strategy will be required to achieve a therapeutic level of liver repopulation with bone marrow-derived hepatocytes.
- Published
- 2002
- Full Text
- View/download PDF
50. Liver repopulation by Bcl-x(L) transgenic hepatocytes.
- Author
-
Mitchell C, Mallet VO, Guidotti JE, Goulenok C, Kahn A, and Gilgenkrantz H
- Subjects
- Animals, Animals, Genetically Modified genetics, Antibodies pharmacology, Apoptosis physiology, Liver drug effects, Mice, Mice, Inbred CBA, Mice, Inbred Strains, Proto-Oncogene Proteins c-bcl-2 genetics, bcl-X Protein, fas Receptor immunology, fas Receptor physiology, Hepatocytes cytology, Hepatocytes physiology, Liver cytology, Liver physiology, Liver Regeneration physiology, Proto-Oncogene Proteins c-bcl-2 metabolism
- Abstract
Liver repopulation could constitute a potential therapeutic alternative to liver transplantation in the future. Therefore, the development of liver repopulation strategies is of major interest. We have previously reported that Bcl-2-expressing hepatocytes are resistant to Fas-mediated apoptosis and that these hepatocytes, when transplanted into the spleen, are able to repopulate the liver of normal mice submitted to Fas-mediated apoptosis. We now show that Bcl-x(L)-overexpressing hepatocytes are able to repopulate up to 10% of a normal mouse liver treated with successive injections of anti-Fas antibody. We show that a twofold overexpression of Bcl-x(L) is sufficient to confer a selective advantage to hepatocytes submitted to anti-Fas antibody. Moreover, repopulation percentages obtained here were comparable to those obtained when Bcl-2 hepatocytes were transplanted, suggesting that both proteins are equivalent in conferring a selective advantage to hepatocytes submitted to anti-Fas antibody.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.